Invest
Healthcare Services company Dr. Lal Pathlabs announced Q3FY24 & 9MFY24 results:
Q3FY24:
- Revenue: In Q3FY24, Dr Lal PathLabs reported a revenue of Rs 539 crore, marking a 10.1% increase from the Rs 489 crore recorded in Q3FY23.
- Operating Expenditure: The operating expenditure rose by 5.8% to Rs 398 crore in the current quarter from Rs 376 crore in the corresponding quarter of the previous fiscal year.
- EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): The Company's EBITDA escalated significantly by 24.6%, amounting to Rs 141 crore as compared to Rs 113 crore in Q3FY23, resulting in an EBITDA margin of 26.1%.
- Profit After Tax (PAT): PAT witnessed a substantial increase of 53.3% to Rs 82 crore in Q3FY24 from Rs 54 crore in Q3FY23, achieving a PAT margin of 15.3%.
- Earnings per Share (EPS): EPS climbed up to Rs 9.8, reflecting a remarkable 53.2% gain over the Rs 6.4 reported in Q3FY23.
9MFY24:
- Revenue: the Company's cumulative revenue reached Rs 1681 crore, which is a 10.2% increment year-on-year.
- Operating Expenditure: operating expenditure increased by 5.6% to Rs 1217 crore.
- EBITDA: EBITDA grew by 24.1% to Rs 465 crore, from Rs 374 crore with an improved margin of 27.6%.
- Profit After Tax (PAT): The nine months ended December 31, 2023, saw PAT soar by 50.5% to Rs 277 crore.
- Earnings per Share (EPS): EPS stood at Rs 32.9, an increase of 49.5% from the previous year.
FAQ’s on Dr Lal Pathlabs Ltd Shares
